Relative tolerability of Alzheimer's disease treatments.
作者： Jeffrey L Cummings , Gustavo Alva
DOI:
关键词:
摘要: Objective: In the US, approved therapies for mild to moderate Alzheimer’s disease (AD) currently comprise three cholinesterase inhibitors (ChEIs: donepezil, galantamine, and rivastigmine), while N-methyl-D-aspartate (NMDA) receptor antagonist memantine ChEI donepezil are severe AD. The purpose of this study is review safety tolerability ChEIs memantine, based upon manufacturers’ data found in prescribing information (PI) documents. Design: Current PI documents
参考文章(18)
Jacqueline S Birks, Cholinesterase inhibitors for Alzheimer's disease Cochrane Database of Systematic Reviews. ,(2006) , 10.1002/14651858.CD005593
Jacqueline S Birks, Richard J Harvey, Donepezil for dementia due to Alzheimer's disease Cochrane Database of Systematic Reviews. ,vol. 6, pp. 1- 338 ,(2006) , 10.1002/14651858.CD001190.PUB3
Clement Loy, Lon Schneider, Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database of Systematic Reviews. ,(2006) , 10.1002/14651858.CD001747.PUB3
Rupert McShane, Almudena Areosa Sastre, Neda Minakaran, Memantine for dementia Cochrane Database of Systematic Reviews. ,vol. 3, pp. 003154- ,(2006) , 10.1002/14651858.CD003154.PUB5
S. E. Black, R. Doody, H. Li, T. McRae, K. M. Jambor, Y. Xu, Y. Sun, C. A. Perdomo, S. Richardson, Donepezil preserves cognition and global function in patients with severe Alzheimer disease Neurology. ,vol. 69, pp. 459- 469 ,(2007) , 10.1212/01.WNL.0000266627.96040.5A
J M. Bland, Statistics Notes: The odds ratio BMJ. ,vol. 320, pp. 1468- 1468 ,(2000) , 10.1136/BMJ.320.7247.1468
Ben Seltzer, Donepezil: an update Expert Opinion on Pharmacotherapy. ,vol. 8, pp. 1011- 1023 ,(2007) , 10.1517/14656566.8.7.1011
Jonathan P. Larco, Dilip V. Jeste, Physical comorbidity and polypharmacy in older psychiatric patients. Biological Psychiatry. ,vol. 36, pp. 146- 152 ,(1994) , 10.1016/0006-3223(94)91220-3
Ravi Anand, Richard Hartman, Hyesung Sohn, Jacquiline Danyluk, Stephen M. Graham, Impact of Study Design and Patient Population on Outcomes From Cholinesterase Inhibitor Trials American Journal of Geriatric Psychiatry. ,vol. 11, pp. 160- 168 ,(2003) , 10.1097/00019442-200303000-00006
H Feldman, S Gauthier, J Hecker, B Vellas, P Subbiah, E Whalen, Donepezil MSAD Study Investigators Group*, None, A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. ,vol. 57, pp. 613- 620 ,(2001) , 10.1212/WNL.57.4.613